Navigation Links
AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
Date:6/17/2013

nt activity was observed in the trial and warrants further single-agent and combination trials evaluating ABT-199/GDC-0199 in patients with CLL. Dose and schedule evaluation will continue.

Of the 56 patients enrolled, 34 were considered high-risk CLL patients – those with deletions of chromosome 17p or whose disease is refractory to fludarabine therapy. In the post-hoc analysis to determine if high-risk CLL patients could have similar response rates to the overall study population, 17 (30%) patients had 17p deletion and 18 (32%) had fludarabine-refractory CLL.

"High-risk CLL patients are a challenging subgroup to treat, as they tend to have disappointing results with conventional chemotherapy regimens," said Professor Andrew Roberts, Hematologist at the Royal Melbourne Hospital and head of Clinical Translation at the Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.  "While still early in the development process, preliminary response rates observed in these patients appear similar to those observed in other CLL patients being treated with ABT-199/GDC-0199.  These data justify further investigation of this compound in patients with 17p deletion and fludarabine-refractory CLL."

During the study, 16 patients discontinued treatment; nine due to progressed disease and seven for other reasons (two due to TLS, three for other illnesses, one for thromboembolic event and one consent withdrawal). The most common hematological adverse events (AEs) during the study were neutropenia (39%), thrombocytopenia (18%) and anemia (13%). The most common non-hematological AEs were diarrhea (41%), nausea (38%), fatigue (29%), upper respiratory tract infection (27%) and cough (23%). In the first study group, TLS occurred in all three of the enrolled patients; once the modified dosing schedule was utilized, three of the 53 patients experienced TLS, one of which was a fatal
'/>"/>

SOURCE AbbVie
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. AbbVie Named to S&P 500 Dividend Aristocrat Index
2. AbbVie Issues Inaugural Full-Year Outlook for 2013
3. AbbVie to Present at Barclays Global Health Care Conference
4. Receptos Licenses Anti-Interleukin-13 Antibody from AbbVie for Phase 2 Development in Orphan Disease
5. AbbVie to Host First-Quarter Earnings Conference Call
6. AbbVie Reports First-Quarter 2013 Financial Results
7. AbbVie CF Scholarship Application Now Available for Exceptional Undergraduate and Graduate Students with Cystic Fibrosis
8. AbbVies Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration
9. AbbVie to Present at Bank of America Merrill Lynch 2013 Health Care Conference
10. AbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease
11. AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Research and Markets  has announced ... Testing Markets (Lab-Based, Professional POC, Home, Employment, Criminal ... http://photos.prnewswire.com/prnh/20130307/600769 ... in IVD testing with competitive participation by top ... criminal justice personnel, and sports use drug tests ...
(Date:8/1/2014)... 1, 2014 Aspire Technology Partners (Aspire) announced today ... from Cisco. This designation recognizes Aspire for delivering outstanding customer ... America . "Achieving exceptional results for our ... Harris , President and CEO of Aspire. "We are pleased ... Gold Star award and are proud to be part of ...
(Date:8/1/2014)... Medical, Inc. (Nasdaq: NXTM ), a leading manufacturer ... Burbank , Chief Executive Officer, and Mathew Towse , ... Annual Canaccord Genuity Growth Conference being held at the InterContinental ... 13 th at 4:30 p.m. ET.  A webcast of ... About NxStage Medical NxStage Medical, ...
Breaking Medicine Technology:Drugs of Abuse Testing Markets (Lab-Based, Professional POC, Home, Employment, Criminal Justice Markets) 2Aspire Technology Partners Recognized By Cisco For Excellence In Customer Satisfaction 2NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2
... Mass. , Feb. 4 Recognizing that corporate ... they contain, Northern Light ( www.northernlight.com ) today announced that ... excess of $2 billion can be searched, analyzed ... been steadily increasing the number of market research sources integrated ...
... N.C. , Feb. 4 Gorbec Pharmaceutical ... prescription pharmaceutical products, is opening a GMP-compliant analytical laboratory ... expand Gorbec,s current services for analytical method development and ... its U.S. customer base as well as develop a ...
Cached Medicine Technology:Northern Light Surpasses $2 Billion Worth of Research Content Integrated Into SinglePoint Strategic Research Portals 2Northern Light Surpasses $2 Billion Worth of Research Content Integrated Into SinglePoint Strategic Research Portals 3Gorbec Pharmaceutical Services, Inc. Announces the Launch of Its GMP Analytical Laboratory in China 2
(Date:8/1/2014)... August 01, 2014 As AndroGel lawsuits ... country, Ronald E. Johnson, Jr. has been appointed as ... and other testosterone medications. Since the Fall of 2013, ... have worked diligently to investigate and prosecute the claims ... and blood clots as a result of taking testosterone. ...
(Date:8/1/2014)... a cancer diagnosis may improve health outcomes for Asian-American ... a researcher at the University of Houston (UH). ... is the writing instruction. Otherwise, writing is just like ... can be therapeutic, but oftentimes we don,t get the ... said Qian Lu, assistant professor and director of the ...
(Date:8/1/2014)... August 01, 2014 Growing prevalence ... and healthcare reforms are boosting healthcare market growth, ... through discounts and increasing generic consumption is a ... 76.7 million in 2013, having grown at a ... 2008. The implementation of the Health Transformation Program ...
(Date:8/1/2014)... Hot off the presses after the announcement of ... World’s Best Awards by Travel + Leisure , The ... Relaxation Day (technically August 15). , The Lodge at ... help guests celebrate relaxation throughout the month of August. ... wellness to carve out time to relax and unwind. ...
(Date:8/1/2014)... 2014 The "Antimicrobial Coatings Market ... Zinc Oxide, Titanium Dioxide, and Zinc Omadine), Application ... Food & Beverages, Textiles, and others), & Geography ... Trends and Forecasts to 2018" analyzes the Antimicrobial ... and trends in the diverse geographical regions. , ...
Breaking Medicine News(10 mins):Health News:Ron Johnson Named Co-Lead Counsel in Lawsuits for Men Injured by AndroGel and Testosterone 2Health News:Expressive writing may help breast cancer survivors 2Health News:Expressive writing may help breast cancer survivors 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 2Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 3Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 4Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 3Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 4
... General Hospital,became the first hospital in Palm Beach County ... Electronic Birth Registry (EBR) system,launched on August 8, Glades ... reducing the costs and processing time. Now,the staff at ... the,report, and get the required electronic signatures -- all ...
... ATSI ), manufacturer and marketer of state-of-the-art ... will present at the,2007 Thomas Weisel Partners Healthcare ... Company,s presentation is scheduled for Wednesday, September,5, 2007 ... and CEO of ATS,Medical, will present a review ...
... Matrixx Initiatives, Inc.,(Nasdaq: MTXX ), an over-the-counter healthcare ... "Better Ways to Get,Better(R)," will be presenting on September ... Conference. The Company will be presenting at 11:30 ... http://www.matrixxinc.com . Interested parties,should login 15 minutes prior ...
... in,health-related research grew by a modest 4.2% from 2005 ... health costs, according,to a report released today by Research!America. ... Science. The nation spent approximately $116 billion last ... and prevent disease and disability. This,represents a decrease relative ...
... in Italian study , , THURSDAY, Aug. 30 (HealthDay News) -- ... of dying in the next year compared to those who ... number of other studies have shown the benefits of using ... instance, the Italian study comes on the heels of a ...
... A drug that shuts down a critical cell-signaling pathway ... brain cancer successfully kills cancer stem cells thought to ... radiation therapy, a Johns Hopkins study shows. , In ... scientists blocked the signaling system, known as Hedgehog, with ...
Cached Medicine News:Health News:Glades General Hospital First in Palm Beach County to Provide On-Site Electronic Birth Registration 2Health News:Glades General Hospital First in Palm Beach County to Provide On-Site Electronic Birth Registration 3Health News:ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference 2Health News:Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference 2Health News:U.S. Research Funding Continues to Flatten as U.S. Health Costs Climb - in August 31 Science 2Health News:Stopping Statins After Stroke Doubles Death Risk 2Health News:Stopping Statins After Stroke Doubles Death Risk 3Health News:Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells 2Health News:Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells 3
ELISA kit for the quantitative determination of autoantibodies to thyroid peroxidase (TPO) in serum...
ELISA kit for the quantitative determination of autoantibodies to thyroglobulin in serum....
... the most potent, naturally secreted estrogen and ... ovary [1]. In the ovary, estradiol is ... a less potent estrogen derived from androstenedione. ... body tissues. In men, small amounts of ...
... troponin I (cTnI) has been useful in ... Emergency Departments (ED) with chest pain. 18-20 ... when blood levels of sensitive and specific ... isoenzyme of creatine kinase (CK-MB), and myoglobin, ...
Medicine Products: